Skip Navigation


JAC Advance Access originally published online on June 16, 2004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
54/2/557    most recent
dkh328v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (19)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Thomson, K. S.
Right arrow Articles by Moland, E. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thomson, K. S.
Right arrow Articles by Moland, E. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy 2004 54(2):557-562; doi:10.1093/jac/dkh328
JAC vol.54 no.2 © The British Society for Antimicrobial Chemotherapy 2004; all rights reserved.

CS-023 (R-115685), a novel carbapenem with enhanced in vitro activity against oxacillin-resistant staphylococci and Pseudomonas aeruginosa

Kenneth S. Thomson* and Ellen Smith Moland

Center for Research in Anti-Infectives and Biotechnology, Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, NE 68178, USA

* Corresponding author. Tel: +1-402-280-4096; Fax: +1-402-280-1225; Email: kstaac{at}creighton.edu

Objective: To compare the in vitro activities of the carbapenem, CS-023, four representative ß-lactam antibiotics and levofloxacin, against 970 Gram-positive or Gram-negative US clinical isolates.

Methods: Susceptibilities of bacteria chosen for their varying levels of resistance to the comparator agents were determined by NCCLS microdilution methodology.

Results: CS-023 exhibited activity comparable to that of imipenem against most Gram-positive isolates, but was ~8-fold more potent against oxacillin-resistant staphylococci. It was comparable to meropenem against most Gram-negative isolates, but was 4- to 8-fold more potent against five isolates of meropenem-resistant Pseudomonas aeruginosa.

Conclusions: If tissue and body fluid concentrations >8 mg/L can safely be achieved, further studies of CS-023 are warranted to determine its clinical efficacy.

Keywords: carbapenems , ß-lactams , imipenem , meropenem


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
A. A. El Solh and A. Alhajhusain
Update on the treatment of Pseudomonas aeruginosa pneumonia
J. Antimicrob. Chemother., August 1, 2009; 64(2): 229 - 238.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
K. Tanaka, H. Mikamo, K. Nakao, T. Ichiishi, T. Goto, Y. Yamagishi, and K. Watanabe
In Vitro Activity of Tomopenem (CS-023/RO4908463) against Anaerobic Bacteria
Antimicrob. Agents Chemother., January 1, 2009; 53(1): 319 - 322.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
Y. Morinaga, K. Yanagihara, S. Nakamura, K. Yamamoto, K. Izumikawa, M. Seki, H. Kakeya, Y. Yamamoto, Y. Yamada, S. Kohno, et al.
In vivo efficacy and pharmacokinetics of tomopenem (CS-023), a novel carbapenem, against Pseudomonas aeruginosa in a murine chronic respiratory tract infection model
J. Antimicrob. Chemother., December 1, 2008; 62(6): 1326 - 1331.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
T. Koga, N. Masuda, M. Kakuta, E. Namba, C. Sugihara, and T. Fukuoka
Potent In Vitro Activity of Tomopenem (CS-023) against Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa
Antimicrob. Agents Chemother., August 1, 2008; 52(8): 2849 - 2854.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
N. L. Mallalieu, S. Lennon, M. Liu, C. Kirkpatrick, R. Robson, E. Luedin, and B. E. Davies
Effect of Impaired Renal Function on the Pharmacokinetics of Tomopenem (RO4908463/CS-023), a Novel Carbapenem
Antimicrob. Agents Chemother., July 1, 2008; 52(7): 2360 - 2366.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
A. P. MacGowan, K. E. Bowker, and A. R. Noel
Pharmacodynamics of the Antibacterial Effect and Emergence of Resistance to Tomopenem, Formerly RO4908463/CS-023, in an In Vitro Pharmacokinetic Model of Staphylococcus aureus Infection
Antimicrob. Agents Chemother., April 1, 2008; 52(4): 1401 - 1406.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
T. Shibayama, Y. Matsushita, K. Kawai, T. Hirota, T. Ikeda, and S. Kuwahara
Pharmacokinetics and Disposition of CS-023 (RO4908463), a Novel Parenteral Carbapenem, in Animals
Antimicrob. Agents Chemother., January 1, 2007; 51(1): 257 - 263.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
T. Shibayama, Y. Matsushita, T. Hirota, T. Ikeda, and S. Kuwahara
Pharmacokinetics of CS-023 (RO4908463), a Novel Parenteral Carbapenem, in Healthy Male Caucasian Volunteers
Antimicrob. Agents Chemother., December 1, 2006; 50(12): 4186 - 4188.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
T. Koga, T. Abe, H. Inoue, T. Takenouchi, A. Kitayama, T. Yoshida, N. Masuda, C. Sugihara, M. Kakuta, M. Nakagawa, et al.
In Vitro and In Vivo Antibacterial Activities of CS-023 (RO4908463), a Novel Parenteral Carbapenem
Antimicrob. Agents Chemother., August 1, 2005; 49(8): 3239 - 3250.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.